Related Experiment Video
Updated: Jan 15, 2026
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
Published on: January 31, 2020
A case series of immune checkpoint inhibitor-induced gastritis
Athanasia Karavasili1, Melina Yerolatsite1, George Zarkavelis1,2
1Department of Medical Oncology, University Hospital of Ioannina, Ioannina, Greece.
Immune checkpoint inhibitors (ICIs) have become a cornerstone in the treatment of various solid tumors due to their proven efficacy. However, their use is associated with immune-related adverse events (irAEs), which arise from the immune response activated by ICIs. Gastrointestinal irAEs are among the most common and often present as diarrhea or colitis, conditions that can sometimes require discontinuation of ICI therapy. Although irAE gastritis is less frequently reported, it can lead to severe complications, such as gastrorrhagia. Diagnosing immune-related gastritis early can be challenging due to its diverse clinical presentations. While glucocorticoids and other immunosuppressive therapies are standard treatments for irAEs, the optimal management strategy and dosing for immune-related gastritis remain unclear. This case series on ga-stritis caused by ICI therapy aims to provide clinicians with valuable insights into this complex condition and its management.
Immune checkpoint inhibitors (ICIs) have become a cornerstone in the treatment of various solid tumors due to their proven efficacy. However, their use is associated with immune-related adverse events (irAEs), which arise from the immune response activated by ICIs. Gastrointestinal irAEs are among the most common and often present as diarrhea or colitis, conditions that can sometimes require discontinuation of ICI therapy. Although irAE gastritis is less frequently reported, it can lead to severe complications, such as gastrorrhagia. Diagnosing immune-related gastritis early can be challenging due to its diverse clinical presentations. While glucocorticoids and other immunosuppressive therapies are standard treatments for irAEs, the optimal management strategy and dosing for immune-related gastritis remain unclear. This case series on ga-stritis caused by ICI therapy aims to provide clinicians with valuable insights into this complex condition and its management.
Related Concept Videos
01:27Gastritis-I: Introduction and Types
Acute gastritis presents as a sudden inflammation triggered by various stressors to the stomach lining, such as exposure to corrosive agents, local irritants like aspirin and other NSAIDs, alcohol consumption, radiation therapy, physical trauma, severe burns, sepsis,...
01:17Gastritis-II: Pathophysiology
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
01:23Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...